Actinium Pharmaceuticals, Inc. (ATNM) intrinsic value & 10-year financials
Actinium Pharmaceuticals, Inc. (ATNM) has a Graham intrinsic value of $80.48 per share. At $1.13 on Oct 17, 2026, the stock trades 99% below that value. Over the last 10 fiscal years revenue shrank 47.0% a year to $90.0K, with an average return on invested capital of 262.0%.
- Graham intrinsic value
- $80.48
- Share price (Oct 17, 2026)
- $1.13
- Price vs Graham value
- 99% below
- Market cap
- $35.3M
- Revenue (FY2025)
- $90.0K
- Revenue growth (10-yr CAGR)
- -47.0%
- ROIC (10-yr avg)
- 262.0%
- Free cash flow (FY2025)
- -$24.7M
ATNM 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $90.0K | -$33.9M | -$1.09 | -$24.7M | -40274.4% | 86.5% |
| FY2024 | — | -$38.2M | -$1.27 | -$33.1M | — | 98.2% |
| FY2023 | $81.0K | -$48.8M | -$1.83 | -$47.5M | -64098.8% | 123.5% |
| FY2022 | $1.0M | -$33.0M | -$1.37 | $8.3M | -3311.1% | 148.0% |
| FY2021 | $1.1M | -$24.8M | -$1.20 | -$21.0M | -2182.2% | 578.7% |
| FY2020 | — | -$22.2M | — | -$21.9M | — | 819.9% |
| FY2019 | — | -$21.9M | — | -$21.5M | — | 579.8% |
| FY2018 | — | -$23.7M | — | -$20.7M | — | 488.3% |
| FY2017 | — | -$26.6M | — | -$21.6M | — | -167.9% |
| FY2016 | — | -$24.3M | — | -$20.8M | — | -135.1% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Actinium Pharmaceuticals, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Actinium Pharmaceuticals, Inc. has earned high returns on invested capital, averaging 34.4% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
Actinium Pharmaceuticals, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Actinium Pharmaceuticals, Inc. is modeled at -47.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $80.48 per share.